Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.530
-0.130 (-7.83%)
At close: Jun 5, 2026, 4:00 PM EDT
1.546
+0.016 (1.07%)
After-hours: Jun 5, 2026, 7:47 PM EDT
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $26.22M in the quarter ending March 31, 2026, with 191.89% growth. This brings the company's revenue in the last twelve months to $92.62M, up 927.90% year-over-year. In the year 2025, Autolus Therapeutics had annual revenue of $75.39M with 644.94% growth.
Revenue (ttm)
$92.62M
Revenue Growth
+927.90%
P/S Ratio
4.40
Revenue / Employee
$122,844
Employees
754
Market Cap
407.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.39M | 65.27M | 644.94% |
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.68M | -73.38% |
| Dec 31, 2022 | 6.38M | 4.87M | 323.23% |
| Dec 31, 2021 | 1.51M | 1.27M | 522.73% |
| Dec 31, 2020 | 242.00K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Sep 30, 2018 | - | - | - |
| Sep 30, 2017 | - | - | - |
| Sep 30, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Prothena Corporation | 57.94M |
| C4 Therapeutics | 34.86M |
| Ovid Therapeutics | 7.12M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.47M |
AUTL News
- 2 days ago - Autolus Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Autolus Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026 - GlobeNewsWire
- 15 days ago - Autolus Therapeutics Slides: Corporate presentation - Filings
- 22 days ago - Autolus Therapeutics price target raised to $10 from $9 at H.C. Wainwright - TheFly
- 22 days ago - Autolus Therapeutics reports Q1 EPS (27c), consensus (26c) - TheFly
- 22 days ago - Autolus Therapeutics backs FY26 revenue view $120M-$135M, consensus $129.39M - TheFly
- 22 days ago - Autolus Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts